Pharmacyclics, Inc. (NASDAQ: PCYC) is one of the best ways to play the hematology cancer drug market as its Ibrutinib is expected to transform the treatment of many blood cancers.
Pharmacyclics' lead drug Ibrutinib is under FDA review for second line chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). It is in pivotal trials for many other indications.
The company is developing Ibrutinib along with Johnson and Johnson (NYSE:JNJ). Ibrutinib is a Bruton's Tyrosine Kinase (BTK) inhibitor, which leads to death of cancerous cells.
The compound is most advanced in CLL and MCL where it is under FDA review in second-line treatment of these patients (Relapsed Refractory or R/R).
Due to its promising activity in R/R CLL, R/R MCL, the FDA has granted "BreakThrough" designation to Ibrutinib in these three indications. Pharmacyclics and JNJ filed for accelerated approval in R/R CLL and R/R MCL in the second quarter of 2013 based on Phase II data, and the FDA's decision is expected by early'14. The potential PDUFA goal date in late February 2014.
Top 5 Defense Stocks To Invest In 2015: Thor Industries Inc.(THO)
Thor Industries, Inc., together with its subsidiaries, manufactures and sells a range of recreation vehicles and small and mid-size buses, as well as related parts and accessories in the United States and Canada. The company offers a range of travel trailers and motorhomes under the trade name of Airstream, which include Airstream Safari, International, Flying Cloud, and Bambi travel trailers, as well as Interstate Class B motorhomes. It also manufactures and sells conventional travel trailers and fifth wheels under the trade names of Dutchmen, Four Winds, Aero, Grand Junction, Colorado, Cruiser, Seville, Zinger, and Sunset Trail; travel trailers and fifth wheels under trade names of Montana, Springdale, Hornet, Sprinter, Outback, Laredo, Everest, Mountaineer, Challenger, Cougar, Komfort, and Trailblazer; and gasoline and diesel Class C, Class A, and Class B motorhomes under the trade names of Four Winds, Hurricane, Windsport, Mandalay, Dutchmen, Chateau, Serrano, Ventura, and Fun Mover. In addition, it manufactures and sells gasoline and diesel Class A motor homes under the trade names of Daybreak, Challenger, Astoria, Tuscany, Outlaw, and Avanti; travel trailers, fifth wheels, truck campers, and park models under the trade name of General Coach; and park models under the trade names of Tranquility, Westchester, and Breckenridge. Further, the company manufactures small and mid-size transit and commercial buses under the trade names of Aerolite, AeroElite, Aerotech, Escort, MST, Transmark, EZ Rider, Axess, Challenger, Defender, Crusader, American Cruiser, Classic Coach, EZ Trans, GC II, and Pacer. It markets its vehicles through independent dealers to municipalities and private purchasers, such as rental car companies and hotels. The company has a joint venture agreement with Cruise America, Inc. to provide short-term rentals of motorized recreation vehicles to the public. Thor Industries was founded in 1980 and is based in Jackson Center, Oh io.
Advisors' Opinion:- [By Laura Brodbeck]
Next week investors will be waiting for several key earnings reports including FedEx Corporation (NYSE: FDX), Thor Industries, Inc. (NYSE: THO), American Eagle Outfitters (NYSE: AEO), and Big Lots, Inc. (NYSE: BIG).
- [By Seth Jayson]
Thor Industries (NYSE: THO ) reported earnings on June 6. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended April 30 (Q3), Thor Industries met expectations on revenues and beat expectations on earnings per share. - [By Lauren Pollock]
Thor Industries Inc.'s(THO) fiscal first-quarter earnings rose 33% on the strength of higher sales and wider margins. But results came in lower than expected.
Top Up And Coming Companies To Invest In 2014: Duke Realty Corporation (DRE)
Duke Realty Corporation operates as a real estate investment trust (REIT) in the United States. It offers leasing, property and asset management, development, construction, build-to-suit, and other tenant-related services. As of December 31, 2006, Duke Realty owned approximately 721 industrial, office, and retail properties comprising 113.8 million rentable square feet, as well as owned 6,400 acres of unencumbered land for development. The company has elected to be taxed as REIT under the Internal Revenue Code. As a REIT, it would not be subject to federal income tax purposes, provided that it distributes at least 90% of its REIT taxable income to its shareholders. The company was founded in 1972 and is headquartered in Indianapolis, Indiana with regional offices in Alexandria, Virginia; Atlanta, Georgia; Cincinnati, Columbus, and Cleveland, Ohio; Chicago, Illinois; Dallas and Houston, Texas; Minneapolis, Minnesota; Nashville, Tennessee; Orlando, Florida; Phoenix, Arizona; Raleigh, North Carolina; St. Louis, Missouri; and Tampa and Weston, Florida.
Advisors' Opinion:- [By Brad Thomas]
Other REITs mentioned: (O), (NNN), (STAG), (DCT), (EGP), (PDM), (DRE), (LRY)
Source: Chambers Street: More Liquidity Magic On The Way In REIT-DomDisclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. (More...)
Top Up And Coming Companies To Invest In 2014: National Oxygen Ltd (NOL)
National Oxygen Limited (NOL) is an India-based company, which is a producer and supplier of industrial gases both in liquid and gaseous forms to industries and hospitals. Its products include oxygen, nitrogen and acetylene. The Company operates in two segments: Industrial Gases, which is engaged in the manufacture of industrial gases, and Windmill, which is engaged in the generation of windmill energy. During the fiscal year ended March 31, 2012 (fiscal 2012), the Company produced 51,07,981 cubic meters of oxygen, 52,138 cubic meters of dissolved acetylene, 30,69,610 cubic meters of nitrogen and 26,86,762 kilowatt hours of windmill energy. It has two industrial gas plants in Tamil Nadu and Pondicherry, and one windmill in Maharashtra. During fiscal 2012, NOL had an installed capacity to produce 2,50,00,000 cubic meters of oxygen, 2,00,000 cubic meters of dissolved acetylene and 44,00,000 kilowatt hours of windmill energy. Advisors' Opinion:- [By John Emerson]
Another huge benefit which was imbedded in the value of RTEC was the tens of millions of net operating losses (NOL) that the company had accrued as a result of the massive accrual losses it would sustain during the credit crisis. These benefits were not reflected on the balance sheet but they would translate into tens of millions of dollars in income tax savings when the company eventually returned to profitability.
Top Up And Coming Companies To Invest In 2014: Marquee Energy Ltd (MQL)
Marquee Energy Ltd. (Marquee), formerly Marquee Petroleum Ltd., is a junior oil and gas company engaged in the acquisition, exploration, development and production of petroleum and natural gas reserves in Western Canada. The Company is focused on the Cardium play of West Central Alberta in the Wilesden Green, Carrot Creek and South Pembina areas. As of December 31, 2011, the Company owned a total of approximately 174,420 gross acres (147,875 net acres) of oil and natural gas leases. In December 2013, it acquired all of the Western Canadian assets of Sonde Resources Corp. (Sonde), including all of its Southern Alberta properties. The Assets are primarily located in Marquee's core area at Michichi, Alberta immediately offsetting Marquee's lands and production. In March 2014, Marquee Energy Ltd completed the acquisition of strategic assets in its oil focused Michichi core area. Advisors' Opinion:- [By John Udovich] Sonde Resources Corp. An oil and gas exploration and production company based in Calgary, Alberta, Sonde Resources Corp held a global portfolio of high potential energy assets including producing oil and natural gas assets in Western Canada and offshore exploration property in North Africa.�Specifically, Sonde Resources Corp had�226,119 gross undeveloped acres in Western Canada and 750,000 acres in a Libya/Tunisia offshore licence. However and last November,�an agreement between Sonde Resources Corp and�Marquee Energy Ltd (CVE: MQL) was announced whereby�the latter�will acquire substantially all of the former���Western Canadian assets, including all of its Southern Alberta properties. These assets�are primarily located in Marquee's core area at Michichi, Alberta, immediately offsetting Marquee's lands and production. Under the deal which concluded at the end of last year, Sonde Resources Corp received 21,182,492 common shares of Marquee Energy Ltd plus $15 million cash with the�shares�being distributed to Sonde Resources Corp's shareholders and Sonde itself retaining the cash�received. In addition, Sonde Resources Corp will retain ownership of about 100,000 net acres of Western Canada exploration assets, split approximately equally between its Eaglesham area Wabamun play and west central Alberta Duvernay play.�Moreover, the company will continue to seek strategic alternatives for this Western Canada exploration acreage, including cash sales, farm-outs, other forms of merger, or other options. Otherwise, Sonde Resources Corp�� business�will focus on�the development of the Zarat field and exploration of the Joint Oil Block in North Africa. On Tuesday, small cap Sonde Resources Corp fell 1.83% to $0.530 (SOQ has a 52 week trading range of $0.51 to $2.11 a share) for a market cap of $29.72 million plus the stock is down 70.5% over the past year and down 55.8% over the past five years.
Top Up And Coming Companies To Invest In 2014: Anika Therapeutics Inc.(ANIK)
Anika Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its products are based on hyaluronic acid (HA), a naturally occurring biocompatible polymer found in the body. The company offers orthobiologics products for providing relief from the pain of osteoarthritis, and regenerating damaged tissue, such as cartilage defects; ORTHOVISC for the treatment of osteoarthritis of the knee and various joints; ORTHOVISC mini for the treatment of osteoarthritis in small joints; and MONOVISC, a single injection product used for the treatment of osteoarthritis in various joints. It also provides wound care products that comprise Hyalograft 3D for the regeneration of skin; and Hyalomatrix for the treatment of burns and ulcers. In addition, the company offers AMVISC, AMVISC Plus, STAARVISC-II, Optivisc, and AnikaVisc which are injectable HA products used as viscoelastic agents in o phthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. Further, it provides INCERT, a HA based product for the prevention of post-surgical adhesions; Hyalobarrier and Hyalobarrier Endo, which are post operative adhesion barriers for abdominal indications; and HYVISC, an injectable HA product used for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine osteoarthritis. Additionally, the company offers Merogel, a product used for the treatment of ear, nose, and throat disorders; and provides dermal fillers for facial wrinkles and scar remediation under the ELEVESS and HYDRELLE brand names. It markets its products directly, as well as through a network of distributors primarily in the United States and Europe. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Advisors' Opinion:- [By STOCKPICKR]
Anika Therapeutics (ANIK), together with its subsidiaries, develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair in the U.S., Europe, and internationally. This stock closed up 2.1% to $48.86 in Monday's trading session.
Monday's Volume: 1.25 million
Three-Month Average Volume: 347,160
Volume % Change: 272%From a technical perspective, ANIK jumped higher here right above some near-term support at $46 with above-average volume. This spike higher on Monday briefly pushed shares of ANIK into breakout territory, since the stock flirted with some near-term overhead resistance levels at $49.21 to $49.37. Shares of ANIK tagged an intraday high of $51.40, before it closed below that level at $48.86. Market players should now look for a continuation move to the upside in the short-term if ANIK manages to take out Monday's high of $51.36 to its 52-week high of $52.49 with high volume.
Traders should now look for long-biased trades in ANIK as long as it's trending above Monday's low of $47.57 or above $46 and then once it sustains a move or close above $51.36 to $52.49 with volume that hits near or above 347,160 shares. If that move begins soon, then ANIK will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $55 to $60.
Top Up And Coming Companies To Invest In 2014: GigaMedia Limited (GIGM)
Gigamedia Limited, through its subsidiaries, primarily engages in the operation of online games for online game players in Asia. The company provides a portfolio of online games, including MahJong, a traditional Chinese tile game; MMORPG, an Internet-based computer game; advanced casual games; and card, chance-based, and simple casual games. It also develops and licenses online poker, casino, and sports betting gaming software solutions, as well as offers application services for the online poker and casino markets primarily in the continental European markets. The company has strategic alliances with SoftStar Entertainment Inc., Neostorm Holdings Limited, XLGames Inc., Access China Holding Limited, Gorilla Banana Entertainment Corp., JC Entertainment Corporation, Possibility Space Incorporated, East Gate Media Contents & Technology Fund, and BetClic. GigaMedia Limited was founded in 1997 and is headquartered in Taipei, Taiwan.
Advisors' Opinion:- [By Eric Volkman]
GigaMedia (NASDAQ: GIGM ) results for the company's fiscal Q4 and 2012 have been released. For the quarter, revenue was $4.8 million, down by 34% from the $7.4 million in the same period the previous year. Attributable net loss, however, narrowed considerably to $15.4 million ($0.30 per diluted share) from Q4 2011's shortfall of $51.3 million ($1.01).
Top Up And Coming Companies To Invest In 2014: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Brian Orelli]
After Sarepta Therapeutics (NASDAQ: SRPT ) announced that it was going to have a conference call today to update investors about its plans for a marketing application with the Food and Drug Administration, I joked on Twitter that the lede for my article, "I couldn't have predicted this," worked either way.
- [By Keith Speights]
Sometimes, even the hint of an unfavorable regulatory decision can impact a biotech stock. Sarepta Therapeutics (NASDAQ: SRPT ) shares lost more than 25% of their value in April. There wasn't an outright adverse FDA decision in this case. Instead, the FDA requested additional information related to a potential accelerated approval for Duchenne muscular dystrophy drug eteplirsen.
- [By Lauren Pollock]
Sarepta Therapeutics Inc.(SRPT) said Wednesday data from a Phase IIb open-label extension study of its experimental muscular dystrophy drug showed a continued stabilization of walking ability in treated patients. Shares surged 19% to $23.80 premarket.
No comments:
Post a Comment